Moderna falls on fears new CDC vaccine advisory panel could cloud RSV shot prospects

Moderna shares fell 2.5% pre-market amid concerns that a newly appointed CDC advisory panel, some members of whom have expressed anti-vaccine sentiments, may not recommend the company's RSV vaccine, mRESVIA, for expanded use in at-risk adults aged 18-59, despite its recent FDA approval for that group. The panel's decision, expected later this month, is viewed as a key sentiment indicator for the vaccine sector, with analysts noting broader declines in the space; GSK, Pfizer, and Novavax also saw pre-market declines.

Analysis

Moderna's shares experienced a 2.5% pre-bell decline, extending a previous session's fall, driven by investor apprehension regarding an upcoming U.S. Centers for Disease Control and Prevention (CDC) advisory panel decision on its respiratory syncytial virus (RSV) vaccine, mRESVIA. Although mRESVIA secured U.S. Food and Drug Administration (FDA) approval on Thursday for expanded use in at-risk adults aged 18 to 59 years, its availability to this demographic hinges on a recommendation from the CDC's Advisory Committee on Immunization Practices (ACIP). Concerns are amplified by the recent overhaul of the ACIP panel by Health Secretary Robert F. Kennedy Jr., who dismissed all 17 members; some new appointees have publicly expressed anti-vaccine views, including skepticism towards mRNA technology, which underpins Moderna's vaccines. William Blair analyst Myles Minter highlighted that the ACIP meeting, scheduled for later this month, will be the "first time for investors to see the refreshed ACIP in action and will be important for sentiment in the vaccine sector, which continues to decline in our view." This negative sentiment is not isolated, as U.S.-listed shares of GSK and Pfizer also fell marginally, while Novavax shares declined 1.7% to $7.03 in premarket trading. The CDC currently recommends Moderna’s vaccine for adults aged 75 and older, and for at-risk adults aged 60 to 74; a previous ACIP recommendation from April for approved RSV vaccines in at-risk adults aged 50 to 59 is still awaiting CDC sign-off, indicating pre-existing regulatory complexities even before the panel's reconstitution.

Key Decisions for Investors

• Investors should closely monitor the upcoming ACIP panel's recommendation for Moderna's mRESVIA in the 18-59 age group, as this decision will be a critical near-term catalyst for MRNA's stock and a gauge for vaccine sector sentiment.
• Be prepared for increased volatility in Moderna's shares and potentially other vaccine stocks, as a negative or restrictive ACIP outcome could significantly dampen investor confidence, particularly concerning mRNA technology and regulatory outlooks.
• Re-evaluate exposure to the vaccine sector, including companies like GSK, Pfizer, and Novavax, by considering the heightened regulatory uncertainty introduced by the ACIP reshuffle and its potential impact on future vaccine recommendations and market adoption.